PBAC's latest decision on Radium-223 dichloride: Recommended with restriction (2017). Considered for Treatment of castration resistant metastatic carcinoma of the prostate in patients with symptomatic bone metastases and no known visceral metastatic disease.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2017
Submissions
1
2017 → 2017
Eligible population
Castration resistant metastatic prostate cancer patients with ≥2 skeletal metastases, WHO performance status ≤2, who have failed or are unsuitable for docetaxel, and have not received prior abiraterone or enzalutamide or have developed intolerance to these agents
Therapy area
Oncology
Line of therapy
Later-line
Evidence base
Meta-analysis
Primary endpoint
Cost-minimisation
Pivotal trial size
301 patients
Key trials
ALSYMPCA, COU-AA-301, TROPIC
Comparator
abiraterone
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis conducted; no ICER calculated by design